Korinna Pilz

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer

Rafael Rosell, G. Robinet, A. Szczęsna et al. · Annals of Oncology · 2007 · 260 citations · Full text

Medicine, Oncology, Pharmacology +15

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

Alexander P. J. Vlaar, Sanne de Bruin, Matthias H. Busch et al. · The Lancet Rheumatology · 2020 · 200 citations · Full text

Life Sciences, Immunology, Infectious Diseases +8

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Alexander P. J. Vlaar, Martin Witzenrath, Pieter van Paassen et al. · The Lancet Respiratory Medicine · 2022 · 142 citations · Full text

Medicine, Infectious Diseases, Pharmacotherapy +12

An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

Walter M. Stadler, David J. Vaughn, Guru Sonpavde et al. · Cancer · 2013 · 106 citations

Medicine, Oncology, Pharmacology +10

A new, simple, bioassay for human IFN-γ

Walter Däubener, Nicole Wanagat, Korinna Pilz et al. · Journal of Immunological Methods · 1994 · 102 citations

Life Sciences, Immunology, Innate Immunity +2